Phosphoinositol 3 Kinase (PI3K)Phosphoinositol 3 kinase (PI3K) defines a class of lipid kinases that have the ability to phosphorylate the inositol ring 3′-OH group in inositol phospholipids and therefore produce phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [1]. PI3K encompasses a family of enzymes divided into: Class IA PI3K which includes three isomers (α, β, δ) and Class IB which include the group (γ) [2,3]. PI3K Class IA is comprised of a regulatory subunit p85 along with a catalytic p110α subunit [4]. Mutations in the gene encoding the catalytic subunit of PI3K p110α, PIK3CA, are found in nearly 33% of clear-cell carcinoma cases [5,6], 20% of endometrioid and clear-cell carcinomas [7], 18-28% of cases of serous cystadenocarcinoma, with enhancement of the signature of activated PI3K in the majority of ovarian cancer cases irrespective of the subtype [8]. PIK3CA mutations are considered driver mutations that provide transformative advantages for high grade serous cancer (HGSC) [9]. Multivariate survival analysis revealed that PI3K protein expression was associated with poor survival in advanced HGSC [10]. In addition, several studies have shown that the rate of mutations in the PI3K pathway, especially in AKT and p70S6K, including missense mutations and amplifications, is correlated with higher rates of chemoresistance [11,12]. Chemo-sensitization could be achieved via downregulation of PI3K and/or its downstream effectors, . The increased activation of PI3K in OvCa and its role as a hub for several cancerpromoting pathways, explain its many implications in cancer progression including oncogenic transformation,